We then focused on the efficacy, side effects, and molecular biomarkers of the current combinatorial strategies of anti-PD-1/PD-L1 in combination with other local or systematic therapeutic regimens for breast cancer therapy, aiming to expand the ideas for developing more effective and less toxic combinatorial strategies with PD-1/PD-L1 blockade (Figure 1). This evidence concerns the gene CD274 and breast cancer.